These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31923861)

  • 21. In silico identification, design and synthesis of novel piperazine-based antiviral agents targeting the hepatitis C virus helicase.
    Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Courtney-Smith M; Brancale A
    Eur J Med Chem; 2017 Jan; 125():1115-1131. PubMed ID: 27810598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance mutations against HCV protease inhibitors and antiviral drug design.
    Shang L; Lin K; Yin Z
    Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
    Lin C; Kwong AD; Perni RB
    Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach.
    Palanisamy N; Lennerstrand J
    Interdiscip Sci; 2018 Mar; 10(1):143-156. PubMed ID: 27311576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review on chemogenomic approaches towards hepatitis C viral targets.
    Venkatesan A; Prabhu Dass J F
    J Cell Biochem; 2019 Aug; 120(8):12167-12181. PubMed ID: 30887580
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B.
    Wang Z; Chen X; Wu C; Xu H; Liu H
    Curr Top Med Chem; 2016; 16(12):1362-71. PubMed ID: 26585935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analogs design, synthesis and biological evaluation of peptidomimetics with potential anti-HCV activity.
    Lasheen DS; Ismail MA; Abou El Ella DA; Ismail NS; Eid S; Vleck S; Glenn JS; Watts AG; Abouzid KA
    Bioorg Med Chem; 2013 May; 21(10):2742-55. PubMed ID: 23583031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and antiviral evaluation of a novel series of homoserine-based inhibitors of the hepatitis C virus NS3/4A serine protease.
    Alexandre FR; Brandt G; Caillet C; Chaves D; Convard T; Derock M; Gloux D; Griffon Y; Lallos L; Leroy F; Liuzzi M; Loi AG; Moulat L; Musiu C; Parsy C; Rahali H; Roques V; Seifer M; Standring D; Surleraux D
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3984-91. PubMed ID: 26231161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach.
    Venkatesan A; Febin Prabhu Dass J
    Life Sci; 2017 Apr; 174():8-14. PubMed ID: 28259653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
    Qiu J; Gong Q; Gao J; Chen W; Zhang Y; Gu X; Tang D
    Eur J Med Chem; 2018 Jan; 144():424-434. PubMed ID: 29288943
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.
    Takaya D; Yamashita A; Kamijo K; Gomi J; Ito M; Maekawa S; Enomoto N; Sakamoto N; Watanabe Y; Arai R; Umeyama H; Honma T; Matsumoto T; Yokoyama S
    Bioorg Med Chem; 2011 Nov; 19(22):6892-905. PubMed ID: 21992802
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes.
    Chatterji U; Bobardt MD; Lim P; Gallay PA
    J Gen Virol; 2010 May; 91(Pt 5):1189-93. PubMed ID: 20107018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
    Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
    Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel therapies for hepatitis C: insights from the structure of the virus.
    Fusco DN; Chung RT
    Annu Rev Med; 2012; 63():373-87. PubMed ID: 21942423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry.
    Ahmed M; Pal A; Houghton M; Barakat K
    ACS Infect Dis; 2016 Nov; 2(11):872-881. PubMed ID: 27933783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
    Tseng CH; Lin CK; Chen YL; Tseng CK; Lee JY; Lee JC
    Eur J Med Chem; 2018 Jan; 143():970-982. PubMed ID: 29232587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multi-target QSAR modelling in the analysis and design of HIV-HCV co-inhibitors: an in-silico study.
    Liu Q; Zhou H; Liu L; Chen X; Zhu R; Cao Z
    BMC Bioinformatics; 2011 Jul; 12():294. PubMed ID: 21774796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and evolution of aloperine derivatives as a new family of HCV inhibitors with novel mechanism.
    Zhang X; Lv XQ; Tang S; Mei L; Li YH; Zhang JP; Jiang JD; Peng ZG; Song DQ
    Eur J Med Chem; 2018 Jan; 143():1053-1065. PubMed ID: 29232582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward the Synthesis of Fluorinated Analogues of HCV NS3/4A Serine Protease Inhibitors Using Methyl α-Amino-β-fluoro-β-vinylcyclopropanecarboxylate as Key Intermediate.
    Milanole G; Andriessen F; Lemonnier G; Sebban M; Coadou G; Couve-Bonnaire S; Bonfanti JF; Jubault P; Pannecoucke X
    Org Lett; 2015 Jun; 17(12):2968-71. PubMed ID: 26053226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
    Ji XY; Chen JH; Zheng GH; Huang MH; Zhang L; Yi H; Jin J; Jiang JD; Peng ZG; Li ZR
    J Med Chem; 2016 Nov; 59(22):10268-10284. PubMed ID: 27783522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.